BMAL1 expression is tied to important cellular processes, including cell proliferation, migration, cell cycle and DNA damage repairing. There is increasing evidence that it regulates the expression of various oncogenes and tumor-suppressor genes in cancer cells. Researchers hypothesized that modulating BMAL1 expression could be a new therapeutic approach for treating cancer, such as triple-negative breast cancer (TNBC).

Neurocrine Biosciences Inc. has discovered new peptides acting as corticotropin-releasing factor CRF2 receptor agonists potentially useful for the treatment of obesity.

Work at Trained Therapeutix Discovery Inc. has led to the development of new mammalian target of rapamycin (mTOR; FRAP1) inhibitors and high-density lipoprotein (HDL)-derived nanoparticles potentially useful for the treatment of autoimmune diseases, transplant rejection, inflammatory and cardiovascular disorders.